Biotechnology company Leucid Bio has established proof-of-concept for CAR-T therapy LEU011 for the treatment of solid tumours. 

LEU011 is being evaluated in the ongoing AERIAL trial, but data has established proof-of-concept by demonstrating key biological activity through evidence of encouraging pharmacokinetic (PK) and pharmacodynamic (PD) profiles. Analysis of post-treatment biopsies, evaluated by ddPCR and RNAScope, has shown tumour infiltration by LEU011 cells. 

To date, treatment with LEU011 has been generally well tolerated. In addition, disease control has been observed in multiple patients treated with the lowest dose of LEU011. Dose-escalation in the AERIAL trial continues as planned, with additional data from the trial anticipated during the first half of 2026. 

“Although preliminary, we are highly encouraged by these initial data from the AERIAL trial which establish proof-of-concept for LEU011 in the treatment of solid tumours,” said Filippo Petti, Chief Executive Officer at Leucid Bio. 

“Furthermore, they highlight LEU011’s dual mechanism of action targeting NKG2D stress ligands for tumour recognition and using CXCR2 signalling to enhance T-cell infiltration into the tumour microenvironment.” 

“Traditionally, CAR-Ts have struggled to deliver robust clinical responses in the treatment of solid tumours,” added Dr John Maher, Chief Scientific Officer at Leucid Bio.  

“We believe these preliminary data highlight the functional activity of LEU011 in the treatment of solid tumours given its unique mechanism of action. We anticipate that the early signals observed to date for LEU011 will continue to improve as we advance through the dose-escalation segment of the AERIAL trial.” 

 

Bruno Quinney, Content Team, DDW